drugset / Trial / NCT01534052
A Study to Assess the Safety of Continued Administration of MDV3100 in Subjects With Prostate Cancer Who Showed Benefit From Prior Exposure to MDV3100
Phase 2
Completed
52 enrolled
Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
Timeline
- Start
- 2011-10-21
- Primary completion
- 2017-04-18
- Completion
- 2017-04-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |